Ventricular arrhythmia. Re-entry ventricular arrhythmia
Conditions
Interventions
Intervention 1: Intervention group: Consumption of 10 mg empagliflozin tablets from Abaidi company under the brand name of Gloripa, once daily in the morning, regardless of food, for 90 days (number=
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age older than 18 years old Heart failure diagnosis ICD implantation > three months before eligibility test Signed, written informed consent to participate in the study
Exclusion criteria
Exclusion criteria: Patients using empagliflozin or other SGLT2 inhibitors before the eligibility test New York Heart Association Class IV heart failure Renal dysfunction (eGFR 3 times higher than upper limit of normal) Body mass index < 18.5 kg/m2 Pregnant or suspected pregnancy Patients with the following events within 3 months before the eligibility test: alteration of antiarrhythmic drug, catheter ablation for ventricular arrhythmia, coronary revascularization, open-heart surgery, development of coronary artery disease, stroke or transient ischemic stroke, seizure, infection requiring hospitalization, heart failure requiring hospitalization Other comorbidities including various infections, major surgery, type 1 diabetes, pituitary or adrenal insufficiency, malnutrition, drug or alcohol abuse or dependence, gastrointestinal diseases, cancer ICDs unable to record cardiac arrhythmias
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of the ventricular arrhythmias (PVC, NSVT, VT, VF). Timepoint: During the three months before the intervention and along the three months of the intervention. Method of measurement: ICD (implantable cardioverter-defibrillator) record. | — |
Secondary
| Measure | Time frame |
|---|---|
| Hospitalization. Timepoint: During the three months before the intervention and along the three months of the intervention. Method of measurement: Questionnaire.;Functional class of heart failure. Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Clinical examination and questionnaire.;Peripheral edema. Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Clinical examination and scale.;Oxygen saturation of the arterial blood (SaO2). Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Pulse oximeter device.;Blood glucose. Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Laboratory.;Blood pressure. Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Sphygmomanometer.;Lipid profile. Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Laboratory. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarshad Abedi Torbati
Mashhad University of Medical Sciences
Outcome results
None listed